References
- Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988; 157: 624–628
- Beneath, JE, Dismukes, WE, Duma, RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126–131
- Stamm, AM, Diasio, RB, Dismukes, WE, et al, additional members of the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83: 236–242
- Sugar AM, Stern JJ, Dupont B. Overview: treatment of cryptococcal meningitis. Rev Infect Dis 1990; 12(Suppl. 3)S338–S348
- Powderly, WG, Saag, MS, Cloud, GA, et al. The NIAID AIDS Clinical Trials Group, and the NIAID Mycoses Study Group. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 793–798
- Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agent Chemother 1988; 32: 1–8
- Saag, MS, Powderly, WG, Cloud, GA, et al, the NIAID Mycoses Study Group and the Clinical Trials Group. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992; 326: 83–89
- Stern, JJ, Hartman, BJ, Sharkey, P, et al. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 1988; 85: 477–480
- Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321: 794–799
- Eng RHK, Bishburg E, Smith SM, Kapila R. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 1986; 81: 19–23
- Velez JD, Allendoerfer R, Luther M, Rinaldi MG, Graybill JR. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993; 168: 508–510
- Ross S, McGough DA, Fothergill AW, Rinaldi MG. In vitro susceptibility testing of D-0870, an investigational antifungal triazole. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. American Society for Microbiology, Washington, DC, 284–284, In Abstract 1045
- National Committee for the Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Proposed Standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, PA 1992
- Pfaller MA, Rinaldi MG. Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin N Am 1993; 7: 435–444
- McGinnis MR, Rinaldi MG. Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. Antibiotics in Laboratory Medicine3rd edn, V Lorian. Williams and Wilkins, Baltimore, MD 1991; 198–257, In
- Rinaldi MG, Howell AW. Antifungal antimicrobics: laboratory evaluation. Diagnostic Procedures for Mycotic and Parasitic Infection7th edn, BB Wentworth. American Public Health Association, Washington, DC 1988; 325–356, In
- Humphrey MJ, Jevons JS, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agent Chemother 1985; 28: 648–653